Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China

被引:17
作者
Lin, Shaoyan [1 ]
Mo, Hongnan [1 ]
Li, Yiqun [1 ]
Guan, Xiuwen [1 ]
Chen, Yimeng [1 ]
Wang, Zijing [1 ]
Yuan, Peng [2 ]
Wang, Jiayu [1 ]
Luo, Yang [1 ]
Fan, Ying [1 ]
Cai, Ruigang [1 ]
Li, Qiao [1 ]
Chen, Shanshan [1 ]
Zhang, Pin [1 ]
Li, Qing [1 ]
Ma, Fei [1 ]
Xu, Binghe [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept VIP Med Serv, Natl Canc Ctr,Canc Hosp, Beijing 100021, Peoples R China
关键词
Advanced breast cancer; Nomogram; Overall survival; Prognosis; Prediction; NOVO STAGE IV; DE-NOVO; DOUBLE-BLIND; WOMEN; TRASTUZUMAB; RECURRENCE; TIME;
D O I
10.1016/j.breast.2020.08.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There is a lack of prognostic models predicting the overall survival (OS) of advanced breast cancer (ABC) patients in China. Methods: Data from the China National Cancer Center database that recorded 4039 patients diagnosed with breast cancer between 1987 and 2019 were extracted and a total of 2263 ABC participants were enrolled in this study, which were further randomized 3:1 and divided into training (n = 1706) and validation (n = 557) groups. The nomogram was built based on independent predictors identified by univariate and multivariate cox regression analyses. The discriminatory and predictive capacities of the nomogram were assessed by Harrell's concordance index (C-index) and calibration plots. Results: Univariate and multivariate analyses found that age, Eastern Cooperative Oncology Group (ECOG) score, T-stage, N-stage, tumor subtype, the presence of distant lymph node (DLN)/liver/brain metastasis, local therapy, efficacy of first-line therapy and metastatic-free interval (MFI) were significantly related to OS (all P < 0.05). These variables were incorporated into a nomogram to predict the 2-year and 3-year OS of ABC patients. The C-indexes of the nomogram were 0.700 (95% confidence interval [CI]: 0.683-0.717) for the training set and 0.686 (95% CI: 0.652-0.719) for the validation set. The calibration curves revealed satisfactory consistency between actual survival and nomogram prediction in both the internal and external validations. The nomogram was capable of stratifying patients into different risk cohorts. Conclusions: We constructed and validated a nomogram that might serve as an efficient tool to provide prognostic prediction for ABC patients and guide the physicians to make personalized treatment decisions. (C) 2020 The Author(s). Published by Elsevier Ltd.
引用
收藏
页码:172 / 180
页数:9
相关论文
共 30 条
[1]   Awareness and current knowledge of breast cancer [J].
Akram, Muhammad ;
Iqbal, Mehwish ;
Daniyal, Muhammad ;
Khan, Asmat Ullah .
BIOLOGICAL RESEARCH, 2017, 50
[2]   Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].
Albain, Kathy S. ;
Barlow, William E. ;
Shak, Steven ;
Hortobagyi, Gabriel N. ;
Livingston, Robert B. ;
Yeh, I-Tien ;
Ravdin, Peter ;
Bugarini, Roberto ;
Boehner, Frederick L. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Winer, Eric P. ;
Hudis, Clifford ;
Ingle, James N. ;
Perez, Edith A. ;
Pritchard, Kathleen I. ;
Shepherd, Lois ;
Gralow, Julie R. ;
Yoshizawa, Carl ;
Allred, D. Craig ;
Osborne, C. Kent ;
Hayes, Daniel F. .
LANCET ONCOLOGY, 2010, 11 (01) :55-65
[3]   Local Treatment of Breast Cancer Liver Metastasis [J].
Bale, Reto ;
Putzer, Daniel ;
Schullian, Peter .
CANCERS, 2019, 11 (09)
[4]   Third consensus on medical treatment of metastatic breast cancer [J].
Beslija, S. ;
Bonneterre, J. ;
Burstein, H. J. ;
Cocquyt, V. ;
Gnant, M. ;
Heinemann, V. ;
Jassem, J. ;
Koestler, W. J. ;
Krainer, M. ;
Menard, S. ;
Petit, T. ;
Petruzelka, L. ;
Possinger, K. ;
Schmid, P. ;
Stadtmauer, E. ;
Stockler, M. ;
Van Belle, S. ;
Vogel, C. ;
Wilcken, N. ;
Wiltschke, C. ;
Zielinski, C. C. ;
Zwierzina, H. .
ANNALS OF ONCOLOGY, 2009, 20 (11) :1771-1785
[5]   4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [J].
Cardoso, F. ;
Senkus, E. ;
Costa, A. ;
Papadopoulos, E. ;
Aapro, M. ;
Andre, F. ;
Harbeck, N. ;
Aguilar Lopez, B. ;
Barrios, C. H. ;
Bergh, J. ;
Biganzoli, L. ;
Boers-Doers, C. B. ;
Cardoso, M. J. ;
Carey, L. A. ;
Cortes, J. ;
Curigliano, G. ;
Dieras, V. ;
El Saghir, N. S. ;
Eniu, A. ;
Fallowfield, L. ;
Francis, P. A. ;
Gelmon, K. ;
Johnston, S. R. D. ;
Kaufmann, B. ;
Koppikar, S. ;
Krop, I. E. ;
Mayer, M. ;
Nakigudde, G. ;
Offersen, B. V. ;
Ohno, S. ;
Pagani, O. ;
Paluch-Shimon, S. ;
Penault-Llorca, F. ;
Prat, A. ;
Rugo, H. S. ;
Sledge, G. W. ;
Spence, D. ;
Thomssen, C. ;
Vorobiof, D. A. ;
Xu, B. ;
Norton, L. ;
Winer, E. P. .
ANNALS OF ONCOLOGY, 2018, 29 (08) :1634-1657
[6]   Survival differences among women with de novo stage IV and relapsed breast cancer [J].
Dawood, S. ;
Broglio, K. ;
Ensor, J. ;
Hortobagyi, G. N. ;
Giordano, S. H. .
ANNALS OF ONCOLOGY, 2010, 21 (11) :2169-2174
[7]   Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis [J].
Dieci, M. V. ;
Barbieri, E. ;
Piacentini, F. ;
Ficarra, G. ;
Bettelli, S. ;
Dominici, M. ;
Conte, P. F. ;
Guarneri, V. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :101-108
[8]   Ten-year survival in women with primary stage IV breast cancer [J].
Eng, Lee Guek ;
Dawood, Shaheenah ;
Sopik, Victoria ;
Haaland, Benjamin ;
San Tan, Pui ;
Bhoo-Pathy, Nirmala ;
Warner, Ellen ;
Iqbal, Javaid ;
Narod, Steven A. ;
Dent, Rebecca .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (01) :145-152
[9]   Predicting and Communicating the Risk of Recurrence and Death in Women With Early-Stage Breast Cancer: A Systematic Review of Risk Prediction Models [J].
Engelhardt, Ellen G. ;
Garvelink, Mirjam M. ;
de Haes, J. C. J. M. ;
van der Hoeven, Jacobus J. M. ;
Smets, Ellen M. A. ;
Pieterse, Arwen H. ;
Stiggelbout, Anne M. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03) :238-+
[10]   The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].
Finn, Richard S. ;
Crown, John P. ;
Lang, Istvan ;
Boer, Katalin ;
Bondarenko, Igor M. ;
Kulyk, Sergey O. ;
Ettl, Johannes ;
Patel, Ravindranath ;
Pinter, Tamas ;
Schmidt, Marcus ;
Shparyk, Yaroslav ;
Thummala, Anu R. ;
Voytko, Nataliya L. ;
Fowst, Camilla ;
Huang, Xin ;
Kim, Sindy T. ;
Randolph, Sophia ;
Slamon, Dennis J. .
LANCET ONCOLOGY, 2015, 16 (01) :25-35